Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Long-term health outcomes in patients with Prader-Willi syndrome. A nationwide cohort study in Denmark.

Hedgeman E, Ulrichsen SP, Carter S, Kreher NC, Malobisky KP, Braun MM, Fryzek J, Olsen MS.

Int J Obes (Lond). 2017 Jun 21. doi: 10.1038/ijo.2017.139. [Epub ahead of print]

PMID:
28634363
2.

Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: a randomized, double-blind, placebo-controlled trial.

McCandless SE, Yanovski JA, Miller J, Fu C, Bird LM, Salehi P, Chan CL, Stafford D, Abuzzahab MJ, Viskochil D, Barlow SE, Angulo M, Myers SE, Whitman BY, Styne D, Roof E, Dykens EM, Scheimann AO, Malloy J, Zhuang D, Taylor K, Hughes TE, Kim DD, Butler MG.

Diabetes Obes Metab. 2017 May 29. doi: 10.1111/dom.13021. [Epub ahead of print]

PMID:
28556449
3.

GLP-1 signalling compensates for impaired insulin signalling in regulating beta cell proliferation in ╬▓IRKO mice.

Kawamori D, Shirakawa J, Liew CW, Hu J, Morioka T, Duttaroy A, Burkey B, Kulkarni RN.

Diabetologia. 2017 May 20. doi: 10.1007/s00125-017-4303-6. [Epub ahead of print]

PMID:
28526921
4.

US immigration order strikes against biotech.

Levin JM, Holtzman SH, Maraganore J, Hastings PJ, Cohen R, Dahiyat B, Adams J, Adams C, Ahrens B, Albers J, Aspinall MG, Audia JE, Babler M, Barrett P, Barry Z, Bermingham N, Bloch S, Blum RI, Bolno PB, Bonney MW, Booth B, Bradbury DM, Brauer SK, Byers B, Cagnoni PJ, Cali BM, Ciechanover I, Clark C, Clayman MD, Cleland JL, Cobb P, Cooper R, Currie MG, Diekman J, Dobmeier EL, Doerfler D, Donley EL, Dunsire D, During M, Eckstein JW, Elenko E, Exter NA, Fleming JJ, Flesher GJ, Formela JF, Forrester R, Francois C, Franklin H, Freeman MW, Furst H, Gage LP, Galakatos N, Gallagher BM, Geraghty JA, Gill S, Goeddel DV, Goldsmith MA, Gowen M, Goyal V, Graney T, Grayzel D, Greene B, Grint P, Gutierrez-Ramos JC, Haney B, Ha-Ngoc T, Harris T, Hasnain F, Hata YS, Hecht P, Henshaw L, Heyman R, Hoppenot H, Horvitz HR, Hughes TE, Hutton WS, Isaacs ST, Jenkins A, Jonker J, Kaplan J, Karsen P, Keiper J, Kim J, Kindler J, King R, King V, Kjellson N, Koenig S, Koenig G, Kolchinsky P, Laikind P, Langer RB, Lee JJ, Leff JS, Leicher BA, Leschly N, Levin A, Levin M, Levine AJ, Levy A, Liu DR, Lodish HF, Lopatin U, Love TW, Macdonald G, Maderis GJ, Mahadevia A, Mahanthappa NK, Martin JF, Martin A, Martucci WE, McArthur JG, McCann CM, McCarthy SA, McDonough CG, Mendlein J, Miller L, Miralles D, Moch KI, More B, Myers AG, Narachi MA, Nashat A, Nelson W, Newell WJ, Olle B, Osborn JE, Owens JC, Pande A, Papadopoulos S, Parker HS, Parmar KM, Patterson MR, Paul SM, Perez R, Perry M, Pfeffer CG, Powell M, Pruzanski M, Purcell DJ, Rakhit A, Ramamoorthi K, Rastetter W, Rawcliffe AA, Reid LE, Renaud RC, Rhodes JP, Rieflin WJ, Robins C, Rocklage SM, Rosenblatt M, Rosin JG, Rutter WJ, Saha S, Samuels C, Sato VL, Scangos G, Scarlett JA, Schenkein D, Schreiber SL, Schwab A, Sekhri P, Shah R, Shenk T, Siegall CB, Simon NJ, Simonian N, Stein J, Su M, Szela MT, Taglietti M, Tandon N, Termeer H, Thornberry NA, Tolar M, Ulevitch R, Vaishnaw AK, VanLent A, Varsavsky M, Vlasuk GP, Vounatsos M, Waksal SG, Warma N, Watts RJ, Werber Y, Westphal C, Wierenga W, Williams DE, Williams LR, Xanthopoulos KG, Zohar D, Zweifach SS.

Nat Biotechnol. 2017 Mar 7;35(3):204-206. doi: 10.1038/nbt.3824. No abstract available.

PMID:
28267733
5.

A randomized, placebo-controlled trial of beloranib for the treatment of hypothalamic injury-associated obesity.

Shoemaker A, Proietto J, Abuzzahab MJ, Markovic T, Malloy J, Kim DD.

Diabetes Obes Metab. 2017 Mar 6. doi: 10.1111/dom.12928. [Epub ahead of print]

PMID:
28261955
6.

The High Direct Medical Costs of Prader-Willi Syndrome.

Shoffstall AJ, Gaebler JA, Kreher NC, Niecko T, Douglas D, Strong TV, Miller JL, Stafford DE, Butler MG.

J Pediatr. 2016 Aug;175:137-43. doi: 10.1016/j.jpeds.2016.05.018. Epub 2016 Jun 6.

7.

The International Development of The Modified Hyperphagia Questionnaire.

Crawford SR, Brown TM, Fehnel SE, Doward L, Nelson L, Chen A, Kim T, Roof E, Dykens EM.

Value Health. 2015 Nov;18(7):A761. doi: 10.1016/j.jval.2015.09.2489. Epub 2015 Oct 20. No abstract available.

8.

Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial.

Kim DD, Krishnarajah J, Lillioja S, de Looze F, Marjason J, Proietto J, Shakib S, Stuckey BG, Vath JE, Hughes TE.

Diabetes Obes Metab. 2015 Jun;17(6):566-72. doi: 10.1111/dom.12457. Epub 2015 Mar 31.

PMID:
25732625
9.

Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study.

McElroy SL, Guerdjikova AI, Kim DD, Burns C, Harris-Collazo R, Landbloom R, Dunayevich E.

Prim Care Companion CNS Disord. 2013;15(3). pii: PCC.12m01494. doi: 10.4088/PCC.12m01494. Epub 2013 Jun 20.

10.

Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women.

Hughes TE, Kim DD, Marjason J, Proietto J, Whitehead JP, Vath JE.

Obesity (Silver Spring). 2013 Sep;21(9):1782-8. doi: 10.1002/oby.20356. Epub 2013 May 25.

11.

Emerging therapies for metabolic diseases--the focus is on diabetes and obesity.

Hughes TE.

Curr Opin Chem Biol. 2009 Jun;13(3):332-7. doi: 10.1016/j.cbpa.2009.04.622. Epub 2009 May 23. Review.

PMID:
19482541
12.

Team work in protein processing.

Hannig G.

Chem Biol. 2007 Jul;14(7):732-4.

Supplemental Content

Loading ...
Support Center